NCT00422656View on ClinicalTrials.gov

Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

November 30, 2012

Conditions
Waldenstrom's Macroglobulinemia
Interventions
DRUG

Perifosine

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT00422656 - Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | Biotech Hunter | Biotech Hunter